Vilazodone Hydrochloride Tablet, Film Coated
Product Images NDC 62332-233

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vilazodone Hydrochloride (NDC 62332-233). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vilazodone-10mg-30s.jpg (Vilazodone 10mg 30s)

Packaging label for Vilazodone Hydrochloride tablets, 10 mg strength. The label indicates the film-coated oral tablets are supplied in a package of 30 tablets. Manufactured by Alembic Pharmaceuticals Limited, Gujarat, India, and for Alembic Pharmaceuticals, Inc., Bedminster, NJ, USA. Storage instructions and pharmacist dispensing guidance are included.*

FDA Label Image

Vilazodone-20mg-30s.jpg (Vilazodone 20mg 30s)

Label for Vilazodone Hydrochloride 20 mg film-coated tablets by Alembic Pharmaceuticals, indicating a 30-tablet supply. Storage instructions specify 25°C with allowed excursions. Label includes NDC 62332-233-30, barcode, and dispensing guidance for pharmacists.*

FDA Label Image

Vilazodone-40mg-30s.jpg (Vilazodone 40mg 30s)

Packaging label for Vilazodone Hydrochloride Tablets 40 mg, film-coated oral tablets. The label indicates a package of 30 tablets, manufactured by Alembic Pharmaceuticals Limited (Formulation Division) in India, for Alembic Pharmaceuticals, Inc. The label includes storage instructions and a barcode with NDC 62332-234-30.*

FDA Label Image

Vilazodone-fig.jpg (Vilazodone Fig)

Chemical structure of Vilazodone Hydrochloride is shown. The diagram depicts the molecular arrangement including characteristic rings, bonds, and HCl substitution typically associated with this active pharmaceutical ingredient.*

FDA Label Image

Figure 3 (Vilazodone Fig3)

Pharmacokinetic (PK) chart showing fold change and 90% confidence intervals in Cmax and AUC for Vilazodone Hydrochloride based on population subgroups: age over 65 years, gender (females), and renal and hepatic impairment (mild, moderate, severe). The data compare these subgroups relative to reference groups, highlighting changes in drug exposure.*

FDA Label Image

Figure 2 (Vilazodone Figr2)

A forest plot figure titled 'Impact of Vilazodone on Other Drug Pharmacokinetics,' showing fold changes and 90% confidence intervals for pharmacokinetic measures of various CYP substrates and P-gp substrates relative to a reference. The x-axis ranges from 0.5 to 2 fold change and includes drugs such as nifedipine, caffeine, debrisoquine, flurbiprofen, mephenytoin, and digoxin with corresponding pharmacokinetic parameters noted. The plot visually compares the effect of vilazodone on these drugs' pharmacokinetics.*

FDA Label Image

Vilazodone-figur1.jpg (Vilazodone Figur1)

A scatter plot titled 'Effect of Other Drugs on Vilazodone Pharmacokinetics' showing fold changes and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC when vilazodone is co-administered with ethanol, CYP3A4 inhibitors (ketoconazole), CYP3A4 inducers (carbamazepine), and proton pump inhibitors (pantoprazole). The x-axis represents change relative to reference from 0.5 to 2, with data points indicating increases or decreases in these pharmacokinetic measures.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.